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ABSTRACT (200 words) 
Exacerbations of chronic obstructive pulmonary disease (COPD) are an 
increasing cause of hospitalizations and are associated with accelerated 
progression of airflow obstruction. Approximately half of COPD exacerbations 
are associated with bacteria and many patients have lower airways 
colonization. This suggests that bacterial infection in COPD could be due to 
reduced pathogen removal. This study investigated whether bacterial 
clearance by macrophages is defective in COPD.  
Phagocytosis of fluorescently labelled polystyrene beads and Haemophillus 
influenzae and Streptococcus pneumoniae by alveolar macrophages and 
monocyte-derived macrophages (MDM) were assessed by fluorimetry and 
flow cytometry. Receptor expression was measured by flow cytometry. 
Alveolar macrophages and MDM phagocytosed polystyrene beads similarly. 
There was no difference in phagocytosis of beads by MDM from COPD 
patients compared with cells from smokers and non-smokers. MDM from 
COPD patients showed reduced phagocytic responses to S.pneumoniae and 
H. influenzae compared with non-smokers and smokers. This was not 
associated with alterations in cell surface receptor expression of TLR2, TLR4, 
MARCO, CD163, CD36 or the mannose receptor. Budesonide, formoterol, or 
azithromycin did not suppress phagocytosis suggesting that reduced 
responses in COPD MDM were not due to medications.  
COPD macrophage innate responses are suppressed and may lead to 
bacterial colonisation and increased exacerbation frequency.  
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung 
disease comprising small airways disease and emphysema [1]. It is currently 
the 6th most common cause of death globally and is predicted to become the 
3rd most common cause of death by 2020 [2]. This may be due to the 
increased incidence of cigarette smoking as this is the most common risk 
factor for COPD and contributes to approximately 85% of all cases. 
Approximately, 15% of smokers will develop COPD whereas the incidence in 
non-smokers is 1.6% [3]. In healthy individuals and smokers without lung 
obstruction, the lower airways are sterile, but in COPD patients there is often 
colonization of the lower respiratory tract, with Streptococcus pneumoniae and 
Haemophilus influenzae being the most common bacterial pathogens [4]. 
Exacerbations of COPD are an increasing cause of hospitalizations in the UK 
[5], are associated with accelerated disease progression [6] and account for 
much of the healthcare costs associated with COPD [7,8]. The causes of 
exacerbations vary, but ~50% of infective exacerbations are bacterial in origin. 
Alveolar macrophages contribute 90-95% of cells found in bronchoalveolar 
lavage fluid and are highly phagocytic, producing multiple inflammatory 
mediators [9]. Moreover, their role in removal of potentially pathogenic micro-
organisms via phagocytosis is essential in maintaining the normally sterile 
environment within the lung. One reason for the increased incidence of 
bacterial infections in the respiratory tract of COPD patients might be failure of 
macrophages to clear pathogens because of reduced phagocytosis due to 
chronic activation [10,11].  
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Alveolar macrophages from COPD patients phagocytose fewer 
apoptotic epithelial cells [12] and Escherichia coli [13] compared with non-
smokers and less H. influenzae compared with smokers without COPD [14]. 
Presently, there are no animal models of this aspect of COPD limiting study to 
primary human cells. Therefore, we compared the phagocytic responses of 
alveolar macrophages and monocyte-derived macrophages (MDM) from 
COPD patients with cells from non-smokers and smokers without lung 
obstruction. The use of MDM examined whether reduced phagocytic 
responses of alveolar macrophages in COPD was due to these cells 
becoming replete or whether differentiation in a specific, pro-inflammatory, 
lung environment was required to establish this defect.  
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METHODS 
Subject selection 
Healthy subjects and smokers were recruited from the NHLI, Royal Brompton 
Hospital, London. COPD subjects were recruited from the Royal Free Hospital, 
London or Wexham Park Hospital, Slough. All subjects gave written informed 
consent as approved by the Royal Brompton and Harefield NHS Trust Ethics 
Committee. Bronchoalveolar lavage (BAL) fluid was obtained from consenting 
patients at St. Mary’s Hospital, London or Wexham Park Hospital, Slough. 
Demographic data are presented in Table 1. COPD patients were significantly 
older than the control groups but there were no differences in smoking history 
with the smoking controls (Table 1). 
 
Cell culture 
Monocytes were isolated from PBMC using a Monocyte Isolation kit II 
(Miltenyi Biotec, Surrey, UK) and cultured in the presence of 2ng/ml GM-CSF 
for 12d to generate MDM as described previously [15]. Alveolar macrophages 
were isolated from BAL fluid as described previously [16].  
 
Phagocytosis assays 
Non-typeable H. influenzae strain 1479 and S. pneumoniae serotype 9V, 
strain 10692 were cultured and heat killed at 60ºC for 2h. Bacteria were 
fluorescently labelled using Alexafluor 488 dye (2mg/ml in DMSO) in the dark, 
at room temperature overnight. The labelled bacteria were washed repeatedly 
in PBS to remove unbound label and resuspended in PBS. For alternative 
experiments, live bacteria were resuspended in broth containing CellTracker 
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Red CMPTX dye (12.5µM) (Molecular Probes, Invitrogen, UK) and incubated 
in the dark at 37oC for 45 min.  The labelled bacteria were washed in D-PBS 
until the free dye was removed and stored at -20 oC.  Fluorescently labelled 
polystyrene beads or bacteria were added to cells and incubated for the times 
indicated. Cells were washed with D-PBS and fluorescence of extracellular 
particles was quenched by adding Trypan blue (2%v/v) for 1 min. Excess fluid 
was removed and fluorescence determined for beads and heat killed bacteria 
using an excitation λ 480nm and emission λ 520nm. For experiments using 
live bacteria, MDM were exposed for 4h prior to measurement in a platereader 
using an excitation λ 570 nm and emission λ 610 nm. Initial experiments and 
pharmacology experiments with E.coli were performed using the Vybrant 
Phagocytosis kit according to the manufacturer’s instructions (Invitrogen Ltd, 
Paisley, UK). Data are presented as phagocytosis relative to the fluorescence 
of each specific bacterium to account for differences in labelling. To confirm 
the labelling procedure was not altering the ability of cells to phagocytose, 
E.coli (strain K12, Sigma, Dorset, UK) were labelled under identical conditions 
and used in comparative experiments. Alternatively, following exposure of 
cells to bacteria as described above, cells were removed from the plate by 
agitation and fluorescence measured using a flow cytometer. 
 
Confocal microscopy 
Macrophages were cultured on Lab-tek Permanox chamber slides and fixed 
with 4%w/v paraformaldehyde.  Nuclei were stained with DAPI and cell 
cytoplasm by incubation with Evans blue dye (0.1%w/v).  Slides were viewed 
on a Leica TCS 4D Confocal microscope with a Krypton-Argon laser to detect 
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fluorescence of the FITC/yellow-green/Alexafluor 488 fluorochromes. Images 
of the three stains (DAPI (blue), Evans Blue (red) and the fluorochromes 
(green)) were overlaid.  
 
Electron microscopy 
MDM were incubated with H. influenzae (1mg/ml, 1h) and fixed by addition of 
glutaraldehyde. Secondary fixation was performed with osmium tetroxide. 
Samples were then suspended in molten 2% (w/v) agar and dehydrated by 
incubation with increasing concentrations of methanol.  Cells were infiltrated 
with propylene oxide and Araldite resin, followed by incubation and 
embedding in Araldite alone. Ultrathin sections were then cut, mounted on 
copper support grids and stained using uranyl acetate and Sato’s lead citrate. 
Grids were transferred to the TEM for visualization.  
 
Flow cytometric analysis of macrophage receptor expression 
MDM were removed from the cell culture plates using non-enzymatic cell 
dissociation solution (Sigma, Dorset, UK), washed in PBS containing bovine 
serum albumin (BSA) (0.5%) and sodium azide (PAB) (0.1%) and then 
resuspended at a concentration of 1 × 106 ml. MDM suspension (180 µl) was 
incubated for 1 h on ice with 20 µl of either the appropriate mouse isotype 
control antibody, or mouse monoclonal antibody against CD14, CD163, CD36, 
mannose receptor, MARCO, PS receptor, HLA-DR, TLR2 and TLR4, all at 
50 µg/ml. The cells were washed twice with PAB and a F(ab)’2 fragment of a 
PE-labelled goat anti-mouse IgG (20 µg/ml) (Dako Ltd, Cambridgeshire, UK) 
was incubated with the cells for 30 min on ice. The cells were washed with 
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PAB and finally resuspended in 300 µL of FACSFlowTM containing 0.5% (v/v) 
formaldehyde prior to analysis on a FACScan cytometer (Becton Dickinson, 
Oxon, UK). Five thousand events were acquired and the fluorescence staining 
of the MDM was assessed at 575 nm. The specific mean fluorescence (SMF) 
values were calculated as the fold difference of the mean fluorescence 
intensity (MFI) the isotype control to the MFI of the test antibody. 
 
Statistical Analysis 
Data are presented as mean ± SEM for ‘n’ observations. Comparisons 
between subject groups or cell types were performed using Kruskal-Wallis 
analysis using GraphPad Prism software followed by Dunn’s multiple 
comparison test (GraphPad Software Inc., San Diego, CA) or a Mann-Whitney 
test where appropriate. Differences were considered significant where p<0.05.  
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RESULTS 
Comparison of alveolar macrophage and MDM phagocytosis 
Initial experiments demonstrated that phagocytosis of polystyrene 
beads by both alveolar macrophages and MDM were similar (Fig. 1a). 
Moreover, MDM from non-smokers, smokers and COPD patients 
phagocytosed beads equally (Fig. 1b) which was confirmed as internalization 
by confocal microscopy (Fig. 1c). This would indicate that the MDM model 
reflects alveolar macrophage phagocytosis and that inert particle removal is 
not altered in COPD. In order to ascertain whether similar responses were 
observed when macrophages were exposed to bacteria, a series of 
experiments were devised. Alveolar macrophages from COPD patients 
phagocytosed less E. coli compared with cells from non-smokers and 
smokers (Fig. 2a). By contrast, monocytes from each of the subject groups 
had low phagocytic responses that did not differ with either smoking or 
disease status (Fig. 2b). However, MDM from COPD patients exhibited a 
reduced capacity to ingest bacteria similar to that of alveolar macrophages 
(Fig.2c). We confirmed this observation using FACS analysis. Phagocytosis 
by MDM from non-smokers and smokers were similar (Figs. 2d and e) but 
cells from COPD patients exhibited a significant curve shift to the left (Fig. 2f), 
indicating that fewer cells had engulfed bacteria. These comparative 
phagocytosis experiments suggest that in COPD, defective macrophage 
phagocytosis is acquired during differentiation and that MDM may be useful 
for studying the underlying defective mechanism. 
 
MDM phagocytosis of H.influenzae and S.pneumoniae 
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 To investigate whether this reduced phagocytic response to bacteria 
was restricted to E.coli the phagocytic responses of MDM to fluorescently-
labelled H. influenzae, S. pneumoniae and E. coli were evaluated. All MDM 
phagocytosed the three bacterial strains in a concentration-dependent manner 
(Fig. 3a-c) but the response of COPD MDM was attenuated, not only towards 
E. coli (Fig 3a) but also for S. pneumoniae (Fig. 3b) and H. influenzae (Fig. 
2c). To investigate as to whether defective phagocytosis in COPD MDM was 
an artefact of using heat killed bacteria, experiments were devised using 
labelled, live bacteria. Under these conditions, MDM from control subjects 
phagocytosed increased H. influenzae and S. pneumoniae (p<0.05) 
compared with cells from COPD patients (H. influenzae: control – 3587 ± 390 
vs. COPD – 2170 ± 166 fluorescence units, n=9; S. pneumoniae: control – 
3885 ± 344 vs. COPD – 2514 ± 288 fluorescence units, n=9). Confocal 
microscopy confirmed internalization of S.pneumoniae (Fig. 3d) and H. 
influenzae (Fig. 3e) and electron microscopy confirmed bacterial ingestion and 
formation of phagosomes (Fig. 4) indicating that MDM from COPD patients 
have the capacity to mount correct phagocytic responses, albeit attenuated.  
This reduced clearance of bacterial pathogens by macrophages may 
account for increased infections and the concomitant decline in lung function 
observed in COPD. Therefore, we next examined the relationship between 
lung function parameters and phagocytosis. Phagocytic responses of MDM to 
both E. coli, H. influenzae or S.pneumoniae did not correlate with FEV1% 
predicted (r=0.07,  r=-0.05, and r=0.12 respectively). Similarly, FEV1/FVC ratio 
also did not correlate, with phagocytosis of E. coli, H. influenzae or 
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S.pneumoniae (r=-0.12, r=-0.10, and r=0.32 respectively). In addition, there 
was no relationship between phagocytic response and current smoking status. 
Despite COPD patients having smoked more cigarettes than smokers and 
being older (see Table 1) there were no correlations between either age or 
number of cigarettes smoked (pack-years) and phagocytosis of any bacteria 
examined.  
 
Cell surface expression of receptors involved in bacterial recognition 
   There are numerous receptors involved in bacterial recognition by 
macrophages [17,18] thus reduced receptor expression in COPD could 
account for attenuated phagocytosis. However, there were no differences in 
the expression of TLR2, CD14, TLR4, or CD163 on MDM from COPD patients 
compared with cells from the other subject groups (Table 2). There were also 
no differences in expression of non-specific scavenger receptors including the 
mannose receptor, macrophage receptor with collagenous structure (MARCO) 
or CD36 (Table 2). Nor were there any differences in expression of the 
phosphatidylserine (PS) receptor or HLA-DR on these cells (Table 2).  
MDM from COPD patients phagocytosed beads normally (Fig. 1b) 
limiting defective phagocytosis to engulfment of pathogenic bacteria. Since 
there were no differences in expression of a number of receptors considered 
important in recognition of non-opsonized particles (Table 2), the downstream 
mechanisms emanating from receptor ligation that regulate phagocytic 
responses were examined. Pharmacological modulation of these pathways 
was utlilized to investigate whether altered signal transduction could account 
for these observations. The phosphoinositol-3-kinase (PI3K) inhibitor, LY-
 12 
294002 and the p38 inhbitior, SB 203580, inhibited MDM phagocytosis of E. 
coli from all subjects similarly (Figs. S1a and S1c). By contrast, the Rho 
kinase inhibitor, Y-27632, had no effect on phagocytosis at any of the 
concentrations tested (Fig. S1b).   
 
Effect of pharmacological agents on MDM phagocytosis 
COPD patients are currently taking a variety of medicaments to 
ameliorate their symptoms. These include glucocorticosteroids and 
bronchodilators. Therefore, it was possible that systemic effects of these 
drugs could alter the responses of blood-derived macrophages. To test this 
possibility, MDM from non-smokers, smokers and patients with COPD were 
pre-treated with various pharmacological agents prior to phagocytosis assay 
(Fig. 5).  
Exposure of MDM to budesonide improved the phagocytic responses 
of cells from COPD patients and smokers towards both H.influenzae and 
S.pneumoniae (Figs. 5a and 5d). Agents that elevate cAMP are considered to 
be inhibitory for phagocytosis [19], however formoterol did not inhibit 
phagocytosis of the bacteria in this system (Figs. 5b and 5e) but stimulated 
the response of cells from smokers. There was no effect on the responses of 
cells derived from patients with COPD. The macrolide, azithromycin, is 
reported to restore the phagocytic response of alveolar macrophages from 
COPD patients and enable removal of apoptotic cells [20], however in this 
system azithromycin had no effect on the response of cells from patients with 
COPD but improved the responses of cells from smokers (Figs. 5c and 5f). 
Other drugs (tiotropium bromide (10-9-10-6 M) or theophylline (10-8-10-5M)) 
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prescribed commonly to patients with COPD had no effect on the phagocytic 
response (data not shown).  
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DISCUSSION 
Alveolar macrophages are the sentinel cell of the lung, patrolling the 
airways to remove any inhaled particles or pathogens. Failure of this innate 
response could lead to pulmonary damage and persistent infection. These are 
features of COPD and contribute to the worsening of disease. Therefore, this 
study examined, in detail, the phagocytic responses of macrophages to 
physiological lung pathogens in COPD. 
Using a MDM model, we showed no difference in the capacity of cells 
from patients with COPD to remove inert particles. This confirms observations 
in alveolar macrophages from COPD patients where phagocytosis of inert 
beads occurs to the same extent as cells from control subjects [12,21]. 
However, we observed a very clear defect in the phagocytic response of MDM 
and alveolar macrophages from COPD patients to bacteria. This was not an 
artefact of using heat-killed bacteria, since we observed qualitatively similar 
data with live bacteria. Recently, alveolar macrophages from cigarette 
smokers have been shown to have a reduced phagocytic response for 
apoptotic epithelial cells that was associated with suppression of CD31, CD91,  
CD44 and CD71 [22]. The present study did not show any effect of smoking 
on the phagocytic response of MDM or alveolar macrophages for bacteria 
indicating that the mechanisms for apoptotic cell recognition and bacterial 
pathogens are quite distinct. Initial experiments using E.coli did not show a 
clear difference in the phagocytic response of MDM from smokers and COPD 
patients. However, a more detailed analysis using E.coli labelled ‘in-house’ 
showed reduced phagocytosis of this bacterium between cells from smokers 
and COPD patients. This discrepancy might reflect sensitivity of labelling 
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between commercially obtained phagocytic prey and bacteria labelled ‘in-
house’. Another study has suggested previously that alveolar macrophages 
from COPD patients phagocytose less H. influenzae compared with cells from 
smokers but not non-smokers [14]. In contrast to our data, they reported no 
differences in responses of COPD MDM [14]. The reason for this discrepancy 
with our data is unclear but may reflect differences in the methods used to 
differentiate monocytes to MDM. Our methodology employed the use of GM-
CSF which drives monocytes towards a more alveolar macrophage-like 
phenotype [23] and we also further validated our model by comparison with 
alveolar macrophages with respect to phagocytosis of polystyrene beads and 
E. coli. 
Examination of the mechanism of reduced bacterial clearance by 
COPD macrophages led to investigation of cell surface molecules that could 
be responsible for recognition of bacteria leading to phagocytosis. However, 
these analyses indicated that various receptors were expressed similarly on 
MDM from all subject groups. This contrasts to reports that have shown that 
TLR2 is decreased on the surface of alveolar macrophages in smokers and 
patients with COPD [24]. Although, TLR may modulate the phagocytic 
response [25], the observation that removal of both Gram positive and Gram 
negative bacteria is reduced in COPD would suggest that these receptors are 
not pivotal in this response. Furthermore, the concept that reduced alveolar 
macrophage phagocytosis in COPD is due to cells becoming replete in the 
lung environment is unlikely as MDM, differentiated in vitro show the same 
reduced response.   
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Investigation into the cell signalling pathways showed that 
phagocytosis was mediated by a PI-3-kinase dependent mechanism but that 
Rho kinase is unlikely to be involved. Rho kinase is critical in complement 
receptor-mediated but not FcR-mediated phagocytosis [26] and is inhibitory 
during phagocytosis of apoptotic cells [27]. As Y-27632 had no effect on 
phagocytosis of E. coli by MDM, the defective mechanism in COPD cells is 
likely to be distinct from that of apoptotic cells and complement opsonised 
particles. The inhibition of the phagocytic response by a non-selective PI-3-
kinase inhibitor and a p38 inhibitor could limit the benefit of these agents as 
putative anti-inflammatory therapies in diseases such as COPD where the 
phagocytic response in already suppressed. 
Since this study utilised circulating cells that were subsequently 
differentiated, systemic levels of pharmacological agents used for the 
treatment of COPD may be responsible for the suppression of the phagocytic 
response observed in this study. However, none of the pharmaceutical agents 
examined suppressed phagocytosis of either H. influenzae or S.pneumoniae 
in cells from any of subject groups. Therefore, it is unlikely that differences in 
treatment regimes between the COPD patients and the control groups could 
account for the suppressed phagocytic response.  It is of note that budesonide 
stimulated the phagocytic response in MDM obtained from patients with 
COPD. Although glucocorticosteroids do not improve the long term decline in 
lung function observed in COPD patients, they have been shown to reduce 
exacerbation frequency [28]. This may be due to improved phagocytic 
responses of macrophages in the lungs of these patients. However, the 
concentrations of steroid required to significantly improve phagocytosis in vitro 
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are high (10-7-10-6M) and unlike alveolar macrophages from COPD patients, 
MDM do respond to steroids (data not shown). 
In summary, MDM from COPD patients demonstrate reduced 
phagocytosis for common airway pathogens. This defect is specific to 
pathogenic bacteria. MDM from COPD patients are not replete, nor has 
differentiation occurred in a chronically inflamed lung, suggesting that lack of 
pathogen removal is an inherent defect in circulating monocytes from COPD 
patients that unmasks during maturation into macrophages. This defect in 
phagocytosis of bacteria that most frequently cause acute exacerbations of 
COPD is likely to be an important factor leading to colonization of the lower 
airways and the propensity for bacterial exacerbations. Furthermore, the 
persistence of bacteria in the lower airways may act as a chronic antigenic 
drive for pulmonary inflammation and could contribute to the increased 
numbers of T- and B-lymphocytes in the airways of COPD patients [29]. 
Defining the molecular basis of this defect may lead to identification of 
susceptibility markers for airway obstruction in asymptomatic smokers and to 
development of novel therapies that stimulate phagocytic functions, leading to 
sterilisation of the respiratory tract and a reduction in the bacterial load that 
may drive chronic inflammation in COPD patients. 
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FIGURE LEGENDS 
 
Figure 1.  Comparison of alveolar macrophage and MDM phagocytosis 
of beads  
Panel a) alveolar macrophages (open bars), n=7 and MDM (hatched bars) 
n=7, were exposed to fluorescent beads for 6 h. Phagocytosis was measured 
using a fluorometric plate reader. Panel b) comparison of phagocytic capacity 
of MDM from non-smokers (NS) (open bars), n=9, smokers (S) (hatched bars), 
n=13 and COPD patients (solid bars), n=10 following exposure to 50 x 106 
beads/ml for 6h. Data are presented as mean ± SEM. Panel c) Confocal 
micrograph of MDM engulfing fluorescent beads (50 x 106 beads/ml) 
 
Figure 2. Phagocytosis of E. coli by alveolar macrophages, monocytes 
and MDM. 
Panel a) Phagocytic response of alveolar macrophages from non-smokers 
(NS) (open bars), n=5, smokers (S) (hatched bars), n=5 and COPD patients 
(solid bars), n=4 following exposure to 1 mg/ml FITC-E. coli for 1h. Panel b) 
Phagocytic response of monocytes from non-smokers (NS) (open bars), n=4, 
smokers (S) (hatched bars), n=4 and COPD patients (solid bars), n=6 
following exposure to 1 mg/ml FITC-E.coli for 1h.  Panel c) Phagocytic 
response of MDM from non-smokers (NS) (open bars), n=7, smokers (S) 
(hatched bars), n=6 and COPD patients (solid bars), n=8 following exposure 
to 1 mg/ml FITC-E. coli for 1h.  Data are presented as median ± interquartile 
range, where * represents p<0.05 for differences from non-smokers. The 
phagocytic response of MDM to fluorescently labelled E. coli was also 
determined by flow cytometry. Panel d) represents non-smokers, panel e) 
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smokers and panel f) COPD patients. Data is presented of a representative 
FACS histogram where the grey lines are cells in the absence of bacteria and 
the purple lines are cells in the presence of bacteria for at least n=4 
independent experiments.  
 
Figure 3. Phagocytic responses of MDM from non-smokers, smokers 
and COPD patients to pathogenic bacteria. 
MDM were generated from non-smokers (open bars) n=15-16, smokers 
(hatched bars), n=13-14 and COPD patients (solid bars), n=16-17 and 
exposed to increasing concentrations of fluorescently labelled E. coli (panel a), 
S. pneumoniae (panel b) and H. influenzae (panel c) for 1h. Phagocytosis was 
measured using a fluorometric plate reader. Data are presented as median ± 
interquartile range where * indicates p<0.05 and ** p<0.01.  Internalization of 
particles was confirmed using confocal microscopy. Panels d and e show 
representative orthogonal Z-stack views of phagocytosed S. pneumoniae and 
H. influenzae respectively. 
 
Figure 4. Electron microscopy images of MDM phagocytosis of H. 
influenzae. 
MDM were generated from COPD patients and incubated with 1mg/ml H. 
influenzae for 1h. Cells were then fixed, dehydrated and embedded in Araldite 
resin. Ultrathin slices were cut and stained, then viewed on a transmission 
electron microscope. Arrows indicate bacteria. Image a shows a bacterium on 
the surface of a MDM, images b and c show formation of phagocytic cups 
around bacteria, this is proceeded by complete encapsulation by pseudopodia 
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as indicated in images d and e. The bacteria are then transported into the cell 
cytoplasm within a phagosome (image f).  
 
Figure 5. Effects of pharmacological agents on phagocytosis of bacteria 
by MDM. 
MDM from non-smokers (), smokers (▲) and COPD patients () were pre-
treated with budesonide (panels a and d) or formoterol (panels b and e) for 1h 
or azithromycin (panels c and f) for 24h prior to exposure of the cells to either 
1 mg/ml H.influenzae (panels a-c) or S.pneumoniae (panels d-f) for 1h. Data 
were normalised to the phagocytosis response of each cell type in the 
absence of drug (100%). Data are presented as mean ± SEM for n=5-6.  
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Table 1. Study participant demographics 
 
Data are presented as mean ± SEM. 1 pack year represent 20 cigarettes per 
day for 1 year. * represents p<0.001 vs. non smokers, + represents p<0.001 
vs. smokers. 
 
 
 
 
 Non-smokers 
(n=20) 
Smokers (n=17) COPD (n=19) 
Age (years) 48 ± 3 53 ± 2 70 ± 2*+ 
Sex (M:F) 11:9 10:7 11:8 
Smoking history 
(pack years) 
0.0±0.0+ 33.3 ± 4.6  45.0 ± 4.9* 
FEV1 (l) 3.3 ± 0.15 2.9 ± 0.3 1.2 ± 0.1*
+ 
FEV1 % predicted 102.7 ± 2.6 93.8 ± 3.8 50.6 ± 4.0*
+ 
FVC (l) 4.2 ± 0.2 3.8 ± 0.3 2.4 ± 0.3*+ 
FEV1:FVC 0.8 ± 0.03 0.8 ± 0.02 0.5 ± 0.03*
+ 
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Table 2. Receptor expression on monocyte-derived macrophages 
  Non smokers Smokers COPD 
HLA-DR % 
expression 
92.4±2.9 
n=5 
96.7±1.7 
n=6 
93.6±1.7 
n=12 
SMF 9.8±4.3 
n=5 
16.6±2.0 
n=7 
12.8±2.2 
n=12 
CD14 % 
expression 
92.8±3.0 
n=8 
97.5±1.3 
n=5 
97.7±0.5 
n=12 
SMF 18.2±6.3 
n=8 
20.2±2.4 
n=5 
15.8±2.2 
n=12 
TLR2 % 
expression 
5.5±0.6 
n=5 
7.7±4.6 
n=8 
19.7±16.1 
n=6 
SMF 1.2±0.1 
n=5 
1.4±0.3 
n=8 
2.8±1.6 
n=6 
TLR4 % 
expression 
4.1±0.8 
n=5 
2.1±0.4 
n=8 
10.4±6.9 
n=6 
SFI 1.1±0.1 
n=5 
1.0±0.1 
n=8 
1.3±0.2 
n=6 
CD163 % 
expression 
21.1±4.1 
n=7 
22.9±6.1 
n=9 
18.8±2.2 
n=5 
SMF 6.0±0.7 
n=7 
6.2±0.9 
n=9 
4.6±0.6 
n=5 
CD36 % 
expression 
82.2±7.2 
n=7 
87.6±3.0 
n=9 
83.3±5.2 
n=5 
SMF 8.1±1.2 
n=7 
7.4±1.1 
n=9 
7.2±0.8 
n=5 
Mannose 
receptor 
% 
expression 
43.5±9.8 
n=4 
51.2±14.0 
n=8 
32.7±3.2 
n=5 
SMF 2.3±0.2 
n=4 
3.6±0.6 
n=8 
2.3±0.3 
n=5 
MARCO % 
expression 
7.5±1.2 
n=4 
6.9±0.9 
n=4 
5.9±0.6 
n=5 
SMF 2.3±0.2 
n=4 
2.1±0.1 
n=4 
1.7±0.3 
n=5 
PS receptor 
 
% 
expression 
58.2±4.6 
n=7 
64.6±9.8 
n=6 
47.9±0.8 
n=5 
SMF 2.7±0.3 
n=7 
3.0±0.3 
n=6 
2.4±0.1 
n=5 
HLA-DR = human lymphocyte antigen - DR, MARCO = macrophage receptor 
with collagenous structure, PS = phosphatidylserine, SMF = specific mean 
fluorescence, TLR = Toll-like receptor 
Data are presented as mean ± SEM for ‘n’ samples. 
 
 26 
 
 
 
 27 
 
 28 
 
 
 29 
 
 30 
 
 
 
 
 31 
Supplementary Figure Legend 
 
Figure S1. Effect of pharmacological inhibitors on MDM phagocytosis of 
E.coli. 
MDM were generated from non-smokers (open bars), n=4-6, smokers 
(hatched bars), n=4-6 and COPD patients (solid bars), n=5-11, and exposed 
to the PI3 kinase inhibitor, LY-294001 (panel A) and the Rho kinase inhibitor, 
Y-27632 (panel B) or the p38 inhibitor, SB203580 (panel C) prior to exposure 
to FITC-labelled E.coli. Data are presented as % of the response of MDM in 
the absence of the inhibitor (100%) and as mean± SEM. 
 
 
 
